Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
Marte Lie HøivikLydia C T BuerMilada CvancarovaDavid J WarrenNils BolstadBjørn A MoumAsle W MedhusPublished in: Scandinavian journal of gastroenterology (2018)
The present study provides valuable evidence for the safety and effectiveness of switching from originator to biosimilar infliximab over a prolonged period of 18 months and demonstrates that switching was well tolerated and did not affect the long term clinical outcome.